Study Phase 3

Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial

  • 1 CSR Summary Not Available
  • 1 NCT Number Not Available
  • 1 Primary Citation
  • Data Specification Not Available

Trial Information

Generic NameGalantamineProduct NameRAZADYNE®Therapeutic AreaBehaviors and Mental DisordersEnrollment130% FemaleN/A% WhiteN/A
Product ClassAlzheimer's Disease - Cholinesterase InhibitorsSponsor Protocol NumberGAL-CAN-5Data PartnerJohnson & JohnsonCondition StudiedAlzheimer DiseaseMean/Median Age (Years)N/A

Supporting Documentation

  • Protocol with Amendments Available
  • Clinical Study Report Available
Additional Information

Please note: individual participant-level data are not available for this trial. Only the protocol and full clinical study report are available.

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.